Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China
BackgroundTo understand the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in elderly individuals aged 60–70 years in Shanghai after revaccination.MethodsA total of 330 elderly people aged 60–70 years were recruited to study the immunogenicity and safety of PPSV23 rev...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623611/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849423469375127552 |
|---|---|
| author | Jing Qiu Zhi Li Fang Huang Zhuoying Huang Xiufang Liang Juan Li Yuting Liao Xiang Guo Xiaodong Sun |
| author_facet | Jing Qiu Zhi Li Fang Huang Zhuoying Huang Xiufang Liang Juan Li Yuting Liao Xiang Guo Xiaodong Sun |
| author_sort | Jing Qiu |
| collection | DOAJ |
| description | BackgroundTo understand the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in elderly individuals aged 60–70 years in Shanghai after revaccination.MethodsA total of 330 elderly people aged 60–70 years were recruited to study the immunogenicity and safety of PPSV23 revaccination. The group with a history of PPSV23 vaccination and an interval of 5 years or more was selected as the revaccination group (n=220), and the group without any pneumococcal vaccine was selected as the first vaccination group (n=110).ResultsIn terms of immunogenicity, the GMCs of all serotypes before and after immunization were 1.15-21.57 µg/ml and 1.62-33.19 µg/ml, respectively, in the revaccination group, and the GMCs of all serotypes after immunization were higher than those before immunization (P<0.0001). After immunization, the total GMI of antibodies in the revaccination group was lower than that in the first vaccination group [1.62(1.57, 1.67) vs 3.20(2.82, 3.57), P<0.0001], and the GMIs of all serotypes in the revaccination group were also lower than those in the first vaccination group [(1.40-1.92) vs (1.82-4.69), P<0.0001]. In terms of safety, no serious adverse events occurred during the study and all adverse events that occurred were mild or self-limiting. From 0–30 days after immunization, 7 patients in the revaccination group and 14 patients in the first vaccination group experienced adverse events, with incidence rates of 3.18% and 12.73%, respectively, which were lower in the revaccination group than in the first vaccination group (P=0.0008).ConclusionsCompared with those before vaccination, the antibody levels of elderly people aged 60–70 years in Shanghai who were inoculated with PPSV23 for 5 years or more tended to increase but were lower than those in the first vaccination group. The safety of revaccination with PPSV23 was favorable.Clinical Trial Registrationhttp://www.chictr.org.cn, identifier ChiCTR2100042000; http://clinicaltrials.gov, identifier NCT04701788. |
| format | Article |
| id | doaj-art-dd97b7bd0d6b4a9e8a4d261dda1da6fd |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-dd97b7bd0d6b4a9e8a4d261dda1da6fd2025-08-20T03:30:33ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.16236111623611Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, ChinaJing Qiu0Zhi Li1Fang Huang2Zhuoying Huang3Xiufang Liang4Juan Li5Yuting Liao6Xiang Guo7Xiaodong Sun8Department of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, ChinaDepartment of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, ChinaDepartment of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, ChinaDepartment of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, ChinaDepartment of Immunization, Yangpu District Center for Disease Control and Prevention, Shanghai, ChinaDepartment of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, ChinaDepartment of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, ChinaDepartment of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, ChinaDepartment of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, ChinaBackgroundTo understand the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in elderly individuals aged 60–70 years in Shanghai after revaccination.MethodsA total of 330 elderly people aged 60–70 years were recruited to study the immunogenicity and safety of PPSV23 revaccination. The group with a history of PPSV23 vaccination and an interval of 5 years or more was selected as the revaccination group (n=220), and the group without any pneumococcal vaccine was selected as the first vaccination group (n=110).ResultsIn terms of immunogenicity, the GMCs of all serotypes before and after immunization were 1.15-21.57 µg/ml and 1.62-33.19 µg/ml, respectively, in the revaccination group, and the GMCs of all serotypes after immunization were higher than those before immunization (P<0.0001). After immunization, the total GMI of antibodies in the revaccination group was lower than that in the first vaccination group [1.62(1.57, 1.67) vs 3.20(2.82, 3.57), P<0.0001], and the GMIs of all serotypes in the revaccination group were also lower than those in the first vaccination group [(1.40-1.92) vs (1.82-4.69), P<0.0001]. In terms of safety, no serious adverse events occurred during the study and all adverse events that occurred were mild or self-limiting. From 0–30 days after immunization, 7 patients in the revaccination group and 14 patients in the first vaccination group experienced adverse events, with incidence rates of 3.18% and 12.73%, respectively, which were lower in the revaccination group than in the first vaccination group (P=0.0008).ConclusionsCompared with those before vaccination, the antibody levels of elderly people aged 60–70 years in Shanghai who were inoculated with PPSV23 for 5 years or more tended to increase but were lower than those in the first vaccination group. The safety of revaccination with PPSV23 was favorable.Clinical Trial Registrationhttp://www.chictr.org.cn, identifier ChiCTR2100042000; http://clinicaltrials.gov, identifier NCT04701788.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623611/fullelderlyrevaccination23-valent pneumococcal polysaccharide vaccineimmunogenicitysafety |
| spellingShingle | Jing Qiu Zhi Li Fang Huang Zhuoying Huang Xiufang Liang Juan Li Yuting Liao Xiang Guo Xiaodong Sun Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China Frontiers in Immunology elderly revaccination 23-valent pneumococcal polysaccharide vaccine immunogenicity safety |
| title | Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China |
| title_full | Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China |
| title_fullStr | Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China |
| title_full_unstemmed | Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China |
| title_short | Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China |
| title_sort | immunogenicity and safety study of 23 valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60 70 years in shanghai china |
| topic | elderly revaccination 23-valent pneumococcal polysaccharide vaccine immunogenicity safety |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623611/full |
| work_keys_str_mv | AT jingqiu immunogenicityandsafetystudyof23valentpneumococcalpolysaccharidevaccinerevaccinationamongelderlyindividualsaged6070yearsinshanghaichina AT zhili immunogenicityandsafetystudyof23valentpneumococcalpolysaccharidevaccinerevaccinationamongelderlyindividualsaged6070yearsinshanghaichina AT fanghuang immunogenicityandsafetystudyof23valentpneumococcalpolysaccharidevaccinerevaccinationamongelderlyindividualsaged6070yearsinshanghaichina AT zhuoyinghuang immunogenicityandsafetystudyof23valentpneumococcalpolysaccharidevaccinerevaccinationamongelderlyindividualsaged6070yearsinshanghaichina AT xiufangliang immunogenicityandsafetystudyof23valentpneumococcalpolysaccharidevaccinerevaccinationamongelderlyindividualsaged6070yearsinshanghaichina AT juanli immunogenicityandsafetystudyof23valentpneumococcalpolysaccharidevaccinerevaccinationamongelderlyindividualsaged6070yearsinshanghaichina AT yutingliao immunogenicityandsafetystudyof23valentpneumococcalpolysaccharidevaccinerevaccinationamongelderlyindividualsaged6070yearsinshanghaichina AT xiangguo immunogenicityandsafetystudyof23valentpneumococcalpolysaccharidevaccinerevaccinationamongelderlyindividualsaged6070yearsinshanghaichina AT xiaodongsun immunogenicityandsafetystudyof23valentpneumococcalpolysaccharidevaccinerevaccinationamongelderlyindividualsaged6070yearsinshanghaichina |